COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02743078
Recruitment Status : Terminated (Treatment now available commercially)
First Posted : April 19, 2016
Last Update Posted : November 1, 2019
NovoCure Ltd.
Information provided by (Responsible Party):
RTOG Foundation, Inc.

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : October 15, 2019
Actual Study Completion Date : October 15, 2019